Literature DB >> 15145257

Mode of delivery for breech presentation in grandmultiparous women.

A S Kumari1, H Grundsell.   

Abstract

OBJECTIVES: To compare maternal and neonatal outcomes of planned vaginal delivery vs. elective cesarean delivery for breech presentation at term.
METHODS: Retrospective study of term breech deliveries from January 1997 through December 2000. A group of 128 women for whom vaginal delivery was planned was compared with a group of 122 women who had an elective cesarean delivery with regard to neonatal mortality and morbidity (birth trauma, birth asphyxia, hyperbilirubinemia, and duration of stay in the neonatal intensive care unit) and maternal morbidity (infections, hemorrhage, hysterectomy, deep venous thrombosis, and pulmonary embolism).
RESULTS: There was no difference in neonatal mortality and morbidity between the two groups (13.0% vs. 9.4%). There were fewer maternal complications in the planned vaginal group than in the elective cesarean group (5.5% vs. 18%; P<0.01). In the planned vaginal delivery group 70% of multiparas and 85% of grandmultiparas were delivered vaginally compared with 50% of nulliparas.
CONCLUSIONS: In breech presentations at term vaginal delivery can be achieved in 85% of grandmultiparas without significant neonatal morbidity. Elective cesarean section is associated with increased maternal morbidity compared with planned vaginal delivery.

Entities:  

Mesh:

Year:  2004        PMID: 15145257     DOI: 10.1016/j.ijgo.2003.11.017

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  2 in total

1.  Outcome of breech deliveries in cameroonian nulliparous women.

Authors:  Elie Nkwabong; Joseph Nelson Fomulu; Luc Kouam; Pius Chanchu Ngassa
Journal:  J Obstet Gynaecol India       Date:  2012-10-09

2.  Grand multiparity: is it still a risk in pregnancy?

Authors:  Andrew H Mgaya; Siriel N Massawe; Hussein L Kidanto; Hans N Mgaya
Journal:  BMC Pregnancy Childbirth       Date:  2013-12-23       Impact factor: 3.007

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.